Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287204 | 0.93 | CA2 (0.52) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8498240 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8497303 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8497448 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8499782 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8495744 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8498688 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8499024 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL1047918 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 | |
| SCHEMBL8498567 | 0.91 | CA2 (0.53) | TAAR1CA2CYP11B1CYP11B2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240147998-A1 | HERBICIDAL COMPOSITIONS COMPRISING IMIDAZOLINONE-BASED ACETOLACTATE SYNTHASE INHIBITORS AND USES THEREOF | ADAMA AGAN LTD. (IL) | 2024-05-09 | — | — | US | claimed |
| CN-116887675-A | Herbicidal compositions comprising imidazolinone-based acetolactate synthase inhibitors and uses thereof | 安道麦阿甘有限公司 | 2023-10-13 | — | — | CN | claimed |
| WO-2022180626-A1 | HERBICIDAL COMPOSITIONS COMPRISING IMIDAZOLINONE-BASED ACETOLACTATE SYNTHASE INHIBITORS AND USES THEREOF | ADAMA AGAN LTD. (IL) | 2022-09-01 | — | — | WO | claimed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2012047993-A2 | N-HYDROXYPYRIMIDINE-2,4-DIONES AS INHIBITORS OF HIV AND HCV | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-04-12 | — | — | WO | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| EP-0443573-A2 | HIV protease inhibitors containing derived amino acids | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0443560-A2 | HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118344371-A | Azaspiro compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-07-16 | — | — | CN | disclosed |
| US-4324796-A | HYPOGLYCEMIC AGENTS, HYPOKETONEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-04-13 | — | — | US | disclosed |
| WO-1982000643-A1 | SUBSTITUTED OXIRANECARBONIC ACIDS,PREPARATION AND PHARMACEUTICAL UTILISATION THEREOF | BYK GULDEN LOMBERG CHEM FAB (DE) | 1982-03-04 | — | — | WO | disclosed |
| EP-0046590-A2 | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-03 | — | — | EP | disclosed |
| EP-0025192-A2 | Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-03-18 | — | — | EP | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | TAAR1 982/4885CA2 1253/4885CYP11B1 972/4885 |
| US-20240147998-A1 | HERBICIDAL COMPOSITIONS COMPRISING IMIDAZOLINONE-BASED ACETOLACTATE SYNTHASE INHIBITORS AND USES THEREOF | PPOX, ACOX1, PAOX | TAAR1 4190/4885CA2 1294/4885CYP11B1 547/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | TAAR1 982/4885CA2 1253/4885CYP11B1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.